Basic Materials -
Chemicals - NASDAQ - US
$ 9.15
-0.905 %
$ 687 M
Market Cap
-14.85
P/E
1. INTRINSIC VALUE
Balance Sheet
ASP Isotopes Inc. Common Stock
| Current Assets | 65.7 M |
| Cash & Short-Term Investments | 61.9 M |
| Receivables | 734 K |
| Other Current Assets | 3.12 M |
| Non-Current Assets | 28.6 |
| Long-Term Investments | 28.6 |
| PP&E | 23.5 M |
| Other Non-Current Assets | 5.13 M |
| Current Liabilities | 7.06 M |
| Accounts Payable | 1.02 M |
| Short-Term Debt | 1.62 M |
| Other Current Liabilities | 4.41 M |
| Non-Current Liabilities | 41.9 M |
| Long-Term Debt | 36.1 M |
| Other Non-Current Liabilities | 5.74 M |
EFFICIENCY
Earnings Waterfall
ASP Isotopes Inc. Common Stock
| Revenue | 4.14 M |
| Cost Of Revenue | 2.54 M |
| Gross Profit | 1.6 M |
| Operating Expenses | 28 M |
| Operating Income | -26.4 M |
| Other Expenses | 6.07 M |
| Net Income | -32.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
ASP Isotopes Inc. Common Stock
| Net Income | -32.4 M |
| Depreciation & Amortization | 471 B |
| Capital Expenditures | -11.4 M |
| Stock-Based Compensation | 8.56 M |
| Change in Working Capital | 0 |
| Others | -471 B |
| Free Cash Flow | -28.1 M |
Wall Street Analysts Price Targets
ASP Isotopes Inc. Common Stock
Wall Street analysts predict an average 1-year price target for ASPI of $4.5 , with forecasts ranging from
a
low of
$4.5 to a high of $4.5 .
ASPI Lowest Price Target
Wall Street Target
4.5 USD
-50.82%
ASPI Average Price Target
Wall Street Target
4.5 USD
-50.82%
ASPI Highest Price Target
Wall Street Target
4.5 USD
-50.82%
4. DIVIDEND
ANALYSIS
ASPI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
ASP Isotopes Inc. Common Stock
Sold
0-3 MONTHS
6.45 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
256 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
665 K USD 3
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ASP Isotopes Inc. (ASPI) And Encourages Shareholders to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
accessnewswire.com
- 1 week ago
ASP Isotopes Could Be The Next Big Nuclear Play
AI-driven demand for reliable power is fueling a nuclear renaissance, with Google and tech giants investing heavily in next-gen reactor infrastructure. ASP Isotopes stands out for its isotope enrichment technology, strategic TerraPower partnership, and expansion into advanced materials like Silicon-28. ASPI is a high-risk, high-reward pre-revenue play, with strong cash reserves but significant losses and premium valuation metrics reflecting future growth expectations.
seekingalpha.com
- 1 week ago
Renergen's milestone deal shines spotlight on D3 Energy's South African gas potential
In a significant move for the South African gas industry, Renergen Ltd (ASX:RLT, JSE:REN) on May 22 agreed to a merger with ASP Isotopes (NASDAQ:ASPI), positioning itself as a leading global supplier of critical and enriched industrial gases. The transaction, valued at about $160 million, underscores the growing importance of helium and methane resources.
proactiveinvestors.com
- 1 week ago
ASP Isotopes Inc. to host Investor Access Event in South Africa from June 16-18, 2025
WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will host an Investor Access Event in South Africa from June 16-18, 2025.
globenewswire.com
- 2 weeks ago
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
- Gadolinium-160 is a critical precursor isotope for producing Terbium-161, an emerging medical isotope with significant potential in targeted radiotherapies.
globenewswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ASP Isotopes Inc. (ASPI) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
accessnewswire.com
- 2 weeks ago
ASP Isotopes Inc. Announces Pricing of $50 Million Underwritten Registered Direct Offering of Common Stock
WASHINGTON, June 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at a price of $6.65 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions.
globenewswire.com
- 2 weeks ago
ASP Isotopes and Isotopia Announce Supply Agreement for Gadolinium-160 to Accelerate Terbium-161 Production for Advanced Cancer Therapies
PETACH TIKVA, Israel , June 2, 2025 /PRNewswire/ -- ASP Isotopes Inc. (NASDAQ: ASPI) and Isotopia Molecular Imaging Ltd. have entered into a strategic agreement to secure the supply of Gadolinium-160 (Gd-160), a critical precursor isotope for producing Terbium-161 (Tb-161), an emerging medical isotope with significant potential in targeted radiotherapeutics.
prnewswire.com
- 2 weeks ago
ASP Isotopes Inc. (ASPI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
accessnewswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating ASP Isotopes Inc. (ASPI) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
accessnewswire.com
- 2 weeks ago
ASP Isotopes Issues Letter to Shareholders
WASHINGTON, May 29, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann.
globenewswire.com
- 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages ASP Isotopes Inc. (ASPI) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ASP Isotopes Inc. ("ASP Isotopes" or "the Company") (NASDAQ:ASPI). Investors who purchased ASP Isotopes securities prior to October 30, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ASPI.
accessnewswire.com
- 3 weeks ago
8. Profile
Summary
ASP Isotopes Inc. Common Stock ASPI
COUNTRY
US
INDUSTRY
Chemicals
MARKET CAP
$ 687 M
Dividend Yield
0.00%
Description
ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.
Contact
433 Plaza Real, Washington, FL, 33432
aspisotopes.com
IPO
Date
Nov. 10, 2022
Employees
136
Officers
Dr. Xandra van Heerden Ph.D.
Head of Research & Development
Mr. William Eden M.B.E.
Global Head of HR & Director UK Nuclear Operations
Dr. Hendrik Strydom B. Sc, M. Sc, Ph.D.
Chief Technology Officer
Mr. Robert Ainscow
Chief Operating Officer
Ms. Heather Kiessling
Chief Financial Officer
Mr. Hendrik T. van Wyk
Head of Engineering
Dr. Gerdus Kemp M.D., Ph.D.
Medical Director & Chief Executive Officer of Pet Labs
Mr. Paul Elliot Mann C.F.A.
President, Chief Executive Officer & Executive Chairman